DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable

VANCOUVER, British Columbia and MENLO PARK, Calif., June 29, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing new cancer therapies, announced today that Jeffrey Bacha, Chief Executive Officer and Dennis Brown, Chief Scientific Officer have accepted invitations to join the National Brain Tumor Society's (NBTS) Research Roundtable.

The inaugural meeting entitled, "Streamlining Clinical Trials to Accelerate Brain Tumor Drug Development," was held on June 28, 2017 in Washington D.C., and included leaders from the neuro-oncology community and the U.S. FDA. The meeting focused on improving the understanding of how research can better utilize novel endpoints and innovative design to optimize primary brain tumor clinical trials seeking regulatory approval for next generation therapeutic agents.

"Dr. Brown and I are very enthusiastic about the potential of the NBTS Research Roundtable to have a significant impact in the development of new brain tumor treatments," said Mr. Bacha. It is a privilege to work alongside distinguished researchers, colleagues from the National Brain Tumor Society, and the NCI and FDA toward a common goal of bringing better treatments and cures to patients and families battling and surviving brain cancer."

Formed in 2008 by the merger of the National Brain Tumor Foundation and the Brain Tumor Society, the National Brain Tumor Society (NBTS) is the largest non-profit organization dedicated to the brain tumor community in the United States. Both organizations had previously been formed in the 1980s by parents and other individuals who wanted to increase both research funding and access to resources specific to brain tumors. NBTS brings together research and public policy to effect change at all levels of the brain tumor research and development system in order to innovate new, and better treatments to patients. In research, NBTS seeks new therapeutic targets, as well as to improve existing treatments, and encourages research that connects directly to patient care and enhances quality of life for all brain tumor patients. NBTS also provides education and information to help patients, families, and caregivers make informed decisions and develop strong support systems.

"As part of the NBTS roundtable, DelMar will gain important alliances and insights to support the advancement of our research to develop new treatments for brain tumor patients. These relationships will be increasingly valuable as we advance VAL-083 into pivotal clinical trials," added Mr. Bacha.

About DelMar Pharmaceuticals, Inc.

Founded in 2010, DelMar Pharmaceuticals, Inc. is driven by the passion of its leadership to develop and commercialize unique new cancer therapies that save and improve lives in indications where patients are failing or have become intolerable to currently available treatments. DelMar's lead product candidate VAL-083 is currently being advanced into a pivotal Phase 3 clinical trial as a potential new therapy for the treatment of recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 has been extensively studied by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-joins-national-brain-tumor-societys-research-roundtable-300481671.html

SOURCE DelMar Pharmaceuticals, Inc.